Newer treatments for non-Hodgkin's lymphoma: Monoclonal antibodies

ONCOLOGY

Volumn 12, Issue 10 SUPPL. 8, 1998, Pages 63-76

  Maloney, David G ^a   Press, Oliver W ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ASTATINE 211; BISMUTH; CD19 ANTIGEN; CD20 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CHLORAMBUCIL; COPPER 67; CYCLOPHOSPHAMIDE; DOXORUBICIN; FERRITIN ANTIBODY; HLA DR ANTIGEN; IMMUNOGLOBULIN; IMMUNOTOXIN; INTERFERON; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; IODINE 125; IODINE 131; MONOCLONAL ANTIBODY; OKT 4; PREDNISONE; RICIN ANTIBODY; RITUXIMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VINCRISTINE SULFATE; YTTRIUM 90;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; BRONCHOSPASM; CANCER IMMUNOTHERAPY; CHILL; COMPLEMENT DEPENDENT CYTOTOXICITY; DOSE RESPONSE; DRUG MECHANISM; DRUG TARGETING; FEVER; FOLLICULAR LYMPHOMA; HUMAN; HYPOTENSION; IMMUNE DEFICIENCY; NONHODGKIN LYMPHOMA; RASH; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, NON-HODGKIN; RADIOIMMUNOTHERAPY;

EID: 0031761148     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Ehrlich P: On immunity with specific reference to cell life. Proc R Soc Lond 66:424, 1900.
2. Kohler G, Milstein C: Continuous culture of fused cells secreting antibody of predefined specificity. Nature 236:495, 1975.
3. Waldmann TA, Goldman CK, Bongiovanni KF, et al: Therapy of patients with human T-cell lymphotrophic virus I-induced adult T-cell leukemia with anti-Tac, a monoclonal antibody to the receptor for interleukin-2. Blood 72(5): 1805-1816, 1988.
4. Waldmann TA, White JD, Goldman CK, et al: The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 82(6): 1701-1712, 1993.
5. Vuist WM, Levy R, Maloney DG: Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of bcl-2 protein. Blood 83(4):899-906, 1994.
6. Miller RA, Maloney DG, Warnke R, et al: Treatment of B cell lymphoma with monoclonal anti-idiotype antibody. New Eng J Med, 306(9):517-522, 1982.
7. Meeker TC, Lowder J, Maloney DG, et al: A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 65(6):1349-1363, 1985.
8. Brown SL, Miller RA, Horning SJ, et al: Treatment of B-cell lymphomas with anti-idiotype antibodies alone and in combination with alpha Interferon. Blood 13(3):651-661, 1989.
9. Maloney DG, Brown S, Czerwinski DK, et al: Monoclonal anti-idiotype antibody therapy of B cell lymphoma: The addition of a short course of chemotherapy does not prevent the emergence of idiotype negative variant cells. Blood 80(6):1502-1510, 1992.
10. Waldmann TA, White JD, Carrasquillo JA, et al: Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac. Blood 86(11):4063-4075, 1995.
11. Rankin EM, Hekman A, Somers R, et al: Treatment of two patients with B cell lymphoma with monoclonal anti-idiotypic antibodies. Blood 65(6):1373-1381, 1985.
12. Capel PJA, Preijers WMB, Allebes WA, et al: Treatment of chronic lymphocytic leukemia with monoclonal anti-idiotypic antibody. Neth J Med 28:112-118, 1985.
13. Caulfield MJ, Murthy S, Tubbs RR, et al: Treatment of chronic lymphocytic leukemia with an anti-idiotypic monoclonal antibody. Cleve Clin J Med 56(2):182-188, 1989.
14. Allebes W, Knops R, Herold M, et al: Immunotherapy with monoclonal anti-idiotypic antibodies: tumour reduction and lymphokine production. Leuk Res 15(4):215-222, 1991.
15. Hamblin TJ, Stevenson FK, Abdul-Ahad AK, et al: Preliminary experience in treating lymphocytic leukaemia with antibody to immunoglobulin idiotypes on the cell surface. Br J Cancer 42(4):495-502, 1980.
16. Gordon J, Abdul-Ahad AK, Hamblin TJ, et al: Mechanisms of tumor cell escape encountered in treating lymphocytic leukaemia with antiidiotype antibody. Br J Cancer 49:547, 1984.
17. Davis TA, Maloney DG, Czerwinski DK, et al: Anti-idiotype antibodies can induce longterm complete remissions in non-Hodgkin's Lymphoma without eradicating the malignant clone. Blood 92(4):1184-1190, 1998.
18. Meeker T, Lowder J, Cleary ML, et al: Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N Eng J Med 312(26): 1658-1665, 1985.
19. Kwak LW, Campbell MJ, Czerwinski DK, et al: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors [see comments]. N Engl J Med 327(17): 1209-1215, 1992.
20. Hsu FJ, Caspar CB, Czerwinski D, et al: Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Blood 89(9):3129-3135, 1997.
21. Caspar CB, Levy S, Levy R: Idiotype vaccines for non-Hodgkins lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: Comparison of different vaccine formulations. Blood 90(9):3699-3706, 1997.
22. Hawkins RE, Russell SJ, Marcus R, et al: A pilot study of idiotypic vaccination for follicular B-cell lymphoma using a genetic approach. CRC NO: 92/33. Protocol NO: PH1/027. Hum Gene Ther, 8(10):1287-1299, 1997.
23. Press OW, Appelbaum F, Ledbetter JA, et al: Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood 69(2):584-591, 1987.
24. Reff ME, Camer K, Chambers KS, et al: Depletion of B cells in vivo by a chimeric mouse numan monoclonal antibody to CD20. Blood 83(2):435-445, 1984.
25. Demidem A, Lam T, Alas S, et al: Chimeric anti-Cd20 (Idec-C2b8) monoclonal antibody sensitizes a B-cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12(3): 177-186, 1997.
26. Maloney DG, Smith B, Appelbaum FR, et al: The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's Lymphoma (NHL) cell lines. Blood 1996.
27. Maloney DG, Liles TM, Czerwinski DK, et al: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84(8):2457-2466, 1994.
28. Maloney DG, Grillolopez AJ, Bodkin DJ, et al: Idec-C2b8 - Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin 15(10):3266-3274,1997.
29. Maloney DG, Grillo-Lopez AJ, White CA, et al: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90(6):2188-2195, 1997.
30. McLaughlin P, Grillo-Lopez AJ, Link BK, et al: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program (in process citation). J Clin Oncol 16(8):2825-2833, 1998.
31. Czuzman MS, Grillo-Lopez AJ, Saleh M, et al: IDEC-C2B8/CHOP chemoimmunotherapy in patients with low-grade lymphoma: interim clinical and bcl-2 (PCR) results. Ann Oncol 7(1 Suppl):56, 1996.
32. Dyer MJ, Hale G, Hayhoe FG, et al: Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 73(6):1431-1439, 1989.
33. Wing MG, Moreau T, Greenwood J, et al: Mechanism of first-dose cytokine-release syndrome by CAMPATH1 -H: involvement of CD 16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 98(12):2819-2826, 1996.
34. Pawson R, Dyer MJ, Barge R, et al: Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 15(7):2667-2672, 1997.
35. Osterborg A, Dyer MJ, Bunjes D, et al: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 15(4): 1567-1574, 1997.
36. Mehta J, Powles R, Treleaven J, et al: Autologous transplantation with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia: long-term follow-up. Leuk Lymphoma 25(5-6):479-486, 1997.
37. Dyer MJ, Kelsey SM, Mackay MJ, et al: In vivo 'purging' of residual disease in CLL with Campath-1H. Br. J Haematol 97(3):669-672, 1997.
38. Osterborg A, Passas AS, Anagnostopoulos A, et al: Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 93(1):151-153, 1996.
39. Osterborg A, Werner A, Halapi E, et al: Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52). Eur J Haematol 58(1):5-13, 1997.
40. Isaacs JD, Manna VK, Rapson N, et al: CAMPATH-1H in rheumatoid arthritis - an intravenous dose-ranging study. Br J Rheumatol 35(3):231-240, 1996.
41. Hu E, Epstein AL, Naeve GS, et al: A phase la clinical trial of LYM-1 monoclonal an-tibody serotherapy in patients with refractory B cell malignancies. Hematol Oncol 7(2): 155-166, 1989.
42. Hekman A, Honselaar A, Vuist WM, et al: Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody. Cancer Immunol Immunother 32(6):364-372, 1991.
43. Miller RA, Maloney DG, McKillop J, et al: In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood 58(86):78, 1981.
44. Miller RA, Levy R: Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody. Lancet 2:226-229, 1981.
45. Dillman RO, Shawler DL, Sobol RE, et al: Murine monoclonal antibody therapy in two patients with chronic lympocytic leukemia. Blood 59:1026, 1982.
46. Dillman RO, Shawler DL, Dillman JB, et al: Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol 2:881-891, 1984.
47. Dillman RO, Beauregard J, Shawler DL, et al: Continuous infusion of T101 monoclonal antibody in chronic lymphocytic leukemia and cutaneous T-cell lymphoma. J Biol Resp Mod 5(5):394-410, 1986.
48. Knox S, Hoppe RT, Maloney D, et al: Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 87(3):893-899, 1996.
49. Grossbard ML, Lambert JM, Goldmacher VS, et al: Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms. J Clin Oncol 11(4):726-737, 1993.
50. Grossbard ML, Freedman AS, Ritz J, et al: Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood 79(3):576-585, 1992.
51. Grossbard ML, Gribben JG, Freedman AS, et al: Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 81(9):2263-2271, 1993.
52. Grossbard ML, Niedzwiecki D, Nadler LM, et al: Anti-B4-blocked ricin adjuvant therapy post-autologous bone marrow transplant (CALGB 9254): A phase III intergroup study. Proc Am Soc Clin Oncol 17:3a, 1998.
53. Vitetta ES, Stone M, Amlot P, et al: Phase I immunotoxin trial in patients with B-cell lymphoma. Cancer Res 51(15):4052-4058, 1991.
54. Amlot PL, Stone MJ, Cunningham D, Fay J, et al: A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy. Blood 82(9):2624-2633, 1993.
55. Conry RM, Khazaeli MB, Saleh MN, et al: Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: Effect of an intensive schedule of administration. J Immunother Emphasis Tumor Immunol 18(4):231-241, 1995.
56. Stone MJ, Sausville EA, Fay JW, et al: A phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphoma. Blood 88(4):1188-1197, 1996.
57. LeMaistre CF, Rosen, Frankel A, et al: Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T- cell lymphoma. Blood 78(5):1173-1182, 1991.
58. Engert A, Diehl V, Schnell R, et al: A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT- dgA) in patients with refractory Hodgkin's lymphoma. Blood 89(2):403-410, 1997.
59. Kaminski MS, Zasadny KR, Francis IR, et al: Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 329(7):459-465, 1993.
60. Kaminski MS, Zasadny KR, Francis IR, et al: Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol 14(7):1974-1981, 1996.
61. Press OW, Eary JF, Appelbaum FR, et al: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 329(17):1219-1224, 1993.
62. Press OW, Eary JF, Appelbaum FR, et al: Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 346(8971):336-340, 1995.
63. Press OW, Howell-Clark J, Anderson S, et al: Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 83(5):1390-1397, 1994.
64. Press OW, Shan D, Howell-Clark J, et al: Comparative metabolism and retention of iodine-125, yttrium-90, and indium-Ill radioimmunoconjugates by cancer cells. Cancer Res 56(9):2123-2129, 1996.
65. Wilder RB, DeNardo GL, DeNardo SJ: Radioimmunotherapy: recent results and future directions. J Clin Oncol 14(4):1383-1400, 1996.
66. Lenhard Jr, RE, Order SE, Spunberg JJ, et al: Isotopic immunoglobulin: a new systemic therapy for advanced Hodgkin's disease. J Clin Oncol, 3(10):1296-1300, 1985.
67. Herpst JM, Klein JL, Leichner PK, et al: Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment. J Clin Oncol, 13(9):2394-2400, 1995.
68. Vriesendorp HM, Herpst JM, Germack MA, et al: Phase I-II studies of yttrium-labeled antiferritin treatment for end- stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01 [published erratum appears in J Clin Oncol 1991 Aug;9(8):1516]. J Clin Oncol, 9(6):918-928, 1991.
69. Bierman PJ, Vose JM, Leichner PK, et al: Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease. J Clin Oncol 11(4):698-703, 1993.
70. Vriesendorp HM, Morton JD, Quadri SM: Review of five consecutive studies of radiolabeled immunoglobulin therapy in Hodgkin's disease. Cancer Res, 1995, 55(23 Suppl): p. 5888s-5892s.
71. Kaminski MS, Fig LM, Zasadny KR, et al: Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti- CD37 antibody in B-cell lymphoma. J Clin Oncol 10(11): 1696-1711, 1992.
72. Knox SJ, Goris ML, Trisler K, et al: Yttrium-90-labeled Anti-CD20 Monoclonal Antibody Therapy of Recurrent B-Cell Lymphoma. Clin Cancer Res 2:457-470, 1996.
73. Press OW, Eary JF, Badger CC, et al: Treatment of refractory non-Hodgkin's Lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 7(8): 1027-1038, 1989.
74. DeNardo SJ, DeNardo GL, O'Grady LF, et al: Treatment of B cell malignancies with 1311 Lym-1 monoclonal antibodies. Int J Cancer 3(suppl):96-101, 1988.
75. DeNardo GL, DeNardo SJ, O'Grady LF, et al: Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-l. Cancer Res 50(3 Suppl):1014s-1016s, 1990.
76. Lewis JP, Denardo GL, Denardo SJ: Radioimmunotherapy of lymphoma: a UC Davis experience. Hybridoma 14(2): 115-120, 1995.
77. Goldenberg DM, Horowitz JA, Sharkey RM, et al: Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody [see comments]. J Clin Oncol 9(4):548-564, 1991.
78. Juweid M, Sharkey RM, Markowitz A, et al: Treatment of non-Hodgkin's Lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 55(23 Suppl):5899s-5907s, 1995.
79. Parker BA, Vassos AB, Halpem SE, et al: Radioimmunotherapy of human B-cell lymphoma with 90Y-conjugated antiidiotype monoclonal antibody. Cancer Res 50(3 Suppl):1022s-1028s, 1990.
80. White CA, Halpern SE, Parker BA, et al: Radioimmunotherapy of relapsed B-cell lymphoma with yttrium 90 anti- idiotype monoclonal antibodies. Blood 87(9):3640-3649, 1996.
81. Czuczman MS, Straus DJ, Divgi CR, et al: Phase I dose-escalation trial of iodine 131-labeled monoclonal antibody OKB7 in patients with non-Hodgkin's Lymphoma. J Clin Oncol 11(10):2021-2029, 1993.
82. Rosen ST, Zimmer AM, Goldman-Leikin R, et al: Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an 1311-labeled monoclonal antibody: an Illinois Cancer Council Study. J Clin Oncol 5(4):562-573, 1987.
83. Rosen ST, Zimmer AM, Goldman-Leikin R, et al: Progress in the treatment of cutaneous T-cell lymphomas with radiolabeled monoclonal antibodies. Int J Rad Appl Instrum (B), 16(6):667-668, 1989.
84. Knox SJ, Levy R, Hodgkinson S, et al: Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. Blood 77(1):20-30, 1991.
85. Miller RA, Oscroff AR, Strafte PT, et al: Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62(5):988-995, 1983.
86. Bertram JH, Gill PS, Levine AM, et al: Monoclonal antibody T101 in T cell malignancies: a clinical, pharmacokinetic, and immunologic correlation. Blood 68(3):752-761, 1986.
87. Foon KA, Schroff RW, Bunn PA, et al: Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood 64(5):1085-1093, 1984.
88. Vlasveld LT, Hekman A, Vyth-Dreese FA, et al: Treatment of low-grade non-Hodgkin's Lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19. Cancer Immunol Immunother 40(1):31-47, 1995.
89. Simpkin DJ, Mackie TR: EGS4 Monte Carlo determination of the beta dose kernel in water. Med Phys 17(2): 179-186, 1990.